The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Research item on how variations in KRAS-wild status impact Cetuximab effectiveness

coloCan
coloCan CSN Member Posts: 1,944 Member
in Colorectal Cancer #1

www.biomedcentral.com/1471-2407/13/169/abstract

(there's more info in the link attached but this is all rather "technical")

Like Care

Comments

  • steved
    steved CSN Member Posts: 834 Member
    #2
    Interesting

    Increasing thespecificity of chemo would be great. Preventing people who won't benefit from a drug having to be exposed to it will reduce the harm associated with them. 

    Steve

    Like Care
  • coloCan
    coloCan CSN Member Posts: 1,944 Member
    #3
    steved said:

    Interesting

    Increasing thespecificity of chemo would be great. Preventing people who won't benefit from a drug having to be exposed to it will reduce the harm associated with them. 

    Steve

    From one steve to another: there's a little more of such info

    here

    www.onclive.com/publications/obtn/2013/march-2013/molecular-pathways-pathways-and-more-pathways/1 

    Tho EGFR and KRAS get the most attention. (Hope with each passing day you feel better)

     

    Like Care
  • steved
    steved CSN Member Posts: 834 Member
    #4
    coloCan said:

    From one steve to another: there's a little more of such info

    here

    www.onclive.com/publications/obtn/2013/march-2013/molecular-pathways-pathways-and-more-pathways/1 

    Tho EGFR and KRAS get the most attention. (Hope with each passing day you feel better)

     

    Is practice keeping up?

    Meeting with oncologist next week and will ask if testing anything more than kras in practice yet.

    Slowly recovery moving forward here, thanks for your continued academic stimulation,

    Steve

    Like Care
  • coloCan
    coloCan CSN Member Posts: 1,944 Member
    #5
    steved said:

    Is practice keeping up?

    Meeting with oncologist next week and will ask if testing anything more than kras in practice yet.

    Slowly recovery moving forward here, thanks for your continued academic stimulation,

    Steve

    perhaps you'll find this interesting

    http://cancerres.aacrjournals.org/content/73/7/2059

    Seems like every research team has their "pet" biomarker or factor that may predict future,so to speak. All here are aware of CEA but there may be other indicators as well that may be more pertinent

    Like Care

Discussion Boards